-
公开(公告)号：US07875450B2
公开(公告)日：2011-01-25
申请号：US12050892
申请日：2008-03-18
Applicant: John T. Schiller , Bryce Chackerian , Douglas R. Lowy
Inventor： John T. Schiller , Bryce Chackerian , Douglas R. Lowy
CPC classification number: C12N7/00 , A61K38/00 , A61K39/00 , A61K47/6901 , A61K2039/5258 , C07K14/005 , C07K14/525 , C07K14/7158 , C07K16/084 , C07K16/241 , C07K16/2866 , C07K17/00 , C07K2317/34 , C07K2319/20 , C07K2319/40 , C07K2319/74 , C12N2710/14143 , C12N2710/20022 , C12N2710/20023 , C12N2710/22022 , C12N2710/22023
Abstract: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.
Abstract translation: 本文描述的本发明涉及用于在体内刺激针对耐受原的免疫应答的组合物和方法。 提供了关于嵌合或共轭病毒样颗粒的新型生物技术工具，药物，治疗和预防措施以及前述用途的方法用于研究B细胞耐受性和治疗或预防人类疾病，其涉及 B细胞耐受，如慢性病毒感染，慢性炎性疾病和瘤形成。
-
公开(公告)号：US20060210587A1
公开(公告)日：2006-09-21
申请号：US11415611
申请日：2006-05-01
Applicant: John Schiller , Bryce Chackerian , Douglas Lowy
Inventor： John Schiller , Bryce Chackerian , Douglas Lowy
CPC classification number: C12N7/00 , A61K38/00 , A61K39/00 , A61K47/6901 , A61K2039/5258 , C07K14/005 , C07K14/525 , C07K14/7158 , C07K16/084 , C07K16/241 , C07K16/2866 , C07K17/00 , C07K2317/34 , C07K2319/20 , C07K2319/40 , C07K2319/74 , C12N2710/14143 , C12N2710/20022 , C12N2710/20023 , C12N2710/22022 , C12N2710/22023
Abstract: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.
-
公开(公告)号：US09803189B2
公开(公告)日：2017-10-31
申请号：US11895198
申请日：2007-08-23
Applicant: David S. Peabody , Bryce Chackerian
Inventor： David S. Peabody , Bryce Chackerian
IPC: C40B40/02 , C12N15/10 , C07K14/005 , A61K39/00
CPC classification number: C12N15/1037 , A61K2039/5256 , A61K2039/5258 , C07K14/005 , C12N2740/16122 , C12N2795/18123 , C40B40/02
Abstract: The invention is directed to virus-like particles (VLPs) of an RNA bacteriophage that (a) comprises a coat polypeptide of said phage modified by insertion of a heterologous peptide that is displayed on said VLP and (b) encapsidates said bacteriophage mRNA as well as populations of these VLPs, and their uses. The invention is further directed to VLPs that encapsidate heterologous substances, as well as populations of these VLPs and their uses.
-
14.发明申请Immunogenic HPV L2-Containing VLPs and Related Compositions, Constructs, and Therapeutic Methods 有权含免疫原性HPV L2的VLP及相关组合物，构建体和治疗方法公开(公告)号：US20140105924A1
公开(公告)日：2014-04-17
申请号：US13946562
申请日：2013-07-19
Applicant: Bryce Chackerian , David S. Peabody , Ebenezer Tumban
Inventor： Bryce Chackerian , David S. Peabody , Ebenezer Tumban
IPC: A61K39/12
CPC classification number: A61K39/12 , A61K2039/5258 , A61K2039/58 , C12N2710/20034 , C12N2795/18023 , C12N2795/18071
Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.
Abstract translation: 本发明提供免疫治疗和预防性噬菌体病毒样颗粒（VLP），其可用于治疗和预防人乳头状瘤病毒（HPV）感染和相关疾病，包括宫颈癌和与HPV相关的持续感染。 还提供了相关组合物（例如疫苗），核酸构建体和治疗方法。 本发明的VLP和相关组合物诱导针对HPV L2的高滴度抗体应答，并在体内保护免受HPV挑战。 VLP，含VLP的组合物和本发明的治疗方法诱导针对HPV感染的免疫原性应答，赋予HPV感染免疫，防止HPV感染，并降低HPV感染感染的可能性。
-
公开(公告)号：US20110104203A1
公开(公告)日：2011-05-05
申请号：US12943709
申请日：2010-11-10
Applicant: David S. PEABODY , Bryce Chackerian
Inventor： David S. PEABODY , Bryce Chackerian
CPC classification number: C12N15/1037 , A61K2039/5256 , A61K2039/5258 , C07K14/005 , C12N2740/16122 , C12N2795/18123 , C40B40/02
Abstract: The invention is directed to virus-like particles (VLPs) of an RNA bacteriophage that (a) comprises a coat polypeptide of said phage modified by insertion of a heterologous peptide that is displayed on said VLP and (b) encapsidates said bacteriophage mRNA as well as populations of these VLPs, and their uses. The invention is further directed to VLPs that encapsidate heterologous substances, as well as populations of these VLPs and their uses.
Abstract translation: 本发明涉及RNA噬菌体的病毒样颗粒（VLP），其（a）包含通过插入在所述VLP上显示的异源肽修饰的所述噬菌体的外壳多肽，和（b）还包封所述噬菌体mRNA 作为这些VLP的群体及其用途。 本发明还涉及包裹异源物质的VLP以及这些VLP的群体及其用途。
-
Patent Agency Ranking
公开(公告)号：US20080175853A1
公开(公告)日：2008-07-24
申请号：US12050892
申请日：2008-03-18
Applicant: John T. Schiller , Bryce Chackerian , Douglas R. Lowy
Inventor： John T. Schiller , Bryce Chackerian , Douglas R. Lowy
IPC: A61K39/00
CPC classification number: C12N7/00 , A61K38/00 , A61K39/00 , A61K47/6901 , A61K2039/5258 , C07K14/005 , C07K14/525 , C07K14/7158 , C07K16/084 , C07K16/241 , C07K16/2866 , C07K17/00 , C07K2317/34 , C07K2319/20 , C07K2319/40 , C07K2319/74 , C12N2710/14143 , C12N2710/20022 , C12N2710/20023 , C12N2710/22022 , C12N2710/22023
Abstract: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.
Abstract translation: 本文描述的本发明涉及用于在体内刺激针对耐受原的免疫应答的组合物和方法。 提供了关于嵌合或共轭病毒样颗粒的新型生物技术工具，药物，治疗和预防措施以及前述用途的方法用于研究B细胞耐受性和治疗或预防人类疾病，其涉及 B细胞耐受，如慢性病毒感染，慢性炎性疾病和瘤形成。
-
公开(公告)号：US07371572B2
公开(公告)日：2008-05-13
申请号：US10867119
申请日：2004-06-14
Applicant: John T. Schiller , Bryce Chackerian , Douglas R. Lowy
Inventor： John T. Schiller , Bryce Chackerian , Douglas R. Lowy
CPC classification number: C12N7/00 , A61K38/00 , A61K39/00 , A61K47/6901 , A61K2039/5258 , C07K14/005 , C07K14/525 , C07K14/7158 , C07K16/084 , C07K16/241 , C07K16/2866 , C07K17/00 , C07K2317/34 , C07K2319/20 , C07K2319/40 , C07K2319/74 , C12N2710/14143 , C12N2710/20022 , C12N2710/20023 , C12N2710/22022 , C12N2710/22023
Abstract: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.
Abstract translation: 本文描述的本发明涉及用于在体内刺激针对耐受原的免疫应答的组合物和方法。 提供了关于嵌合或共轭病毒样颗粒的新型生物技术工具，药物，治疗和预防措施以及前述用途的方法用于研究B细胞耐受性和治疗或预防人类疾病，其涉及 B细胞耐受，如慢性病毒感染，慢性炎性疾病和瘤形成。
-
18.发明公开公开(公告)号：US20240279295A1
公开(公告)日：2024-08-22
申请号：US18637070
申请日：2024-04-16
Applicant: Bryce CHACKERIAN , Kiran BHASKAR , Jonathan P. HULSE , UNM Rainforest Innovations
Inventor： Bryce CHACKERIAN , Kiran BHASKAR , Jonathan P. HULSE
CPC classification number: C07K14/4747 , A61K39/00115 , A61K2039/5258 , C12N2795/18123 , C12N2795/18134
Abstract: An immunogen includes an immunogenic carrier and an antigenic apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) peptide linked to the immunogenic carrier. In one or more embodiments, the immunogenic carrier is a Qβ virus-like particle (VLP). The immunogen may be formulated into a composition useful for treating inflammatory medical conditions.
-
公开(公告)号：US11633471B2
公开(公告)日：2023-04-25
申请号：US16977648
申请日：2019-03-06
Applicant: UNM Rainforest Innovations , The United States of America, as represented by the Secretary, Department of Health and Human Services , Bryce Chackerian , Alan Remaley , Marcelo Amar , Alexandra Fowler
Inventor： Bryce Chackerian , Alan Remaley , Marcelo Amar , Alexandra Fowler
IPC: A61K39/385 , A61K47/69 , A61K39/00 , A61K45/06 , C12N7/00
Abstract: An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.
-
公开(公告)号：US20210253641A1
公开(公告)日：2021-08-19
申请号：US17259400
申请日：2019-07-16
Applicant: Bryce Chackerian , Oliver Rixe , UNM RAINFOREST INNOVATIONS
Inventor： Bryce Chackerian , Oliver Rixe
Abstract: An immunogen includes an antigenic EGFRvIII peptide linked to a Qβ bacteriophage virus-like particle (VLP) carrier. The antigenic EGFRvIII peptide has at least 53%, at least 61%, at least 69%, at least 76%, at least 84%, or at least 92% sequence similarity amino acid similarity to LEEKKGNYVVTDH (SEQ ID NO:1).
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.019 seconds)
